MyFinsight
Home
Blog
About
Contact
Proceeds from maturities
of marketable...
$60,000K
Proceeds from exercise of
stock options and rsus...
$7,159K
Net cash provided by
(used in) investing...
$36,262K
Net cash provided by
financing activities
$3,217K
Canceled cashflow
$23,738K
Canceled cashflow
$3,942K
Net increase
(decrease) in cash, cash...
$2,486K
Canceled cashflow
$36,993K
Purchases of investments
$19,738K
Milestone payments
related to ipr&d
$4,000K
Stock-based compensation
expense
$6,120K
Charge for in-process
research and development...
$4,000K
Prepaid expenses and
other current assets
-$1,433K
Operating lease
right-of-use assets
$300K
Depreciation expense
$98K
Other non-cash items
-$53K
Accounts payable
$10K
Withholding taxes paid on
stock-based awards
$3,942K
Net cash used in
operating activities
-$36,882K
Effect of exchange rate
changes on cash, cash...
-$111K
Canceled cashflow
$12,014K
Net loss
-$41,284K
Accrued expenses
-$6,674K
Accretion of investment
discounts, net
$609K
Operating lease
liabilities
-$327K
Other assets
$26K
Back
Back
Cash Flow
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)
source: myfinsight.com